Clearside Biomedical Inc

Company Profile

Clearside Biomedical Inc had its IPO on 2016-06-02 under the ticker symbol CLSD.

The company operates in the Healthcare sector and Biotechnology industry. Clearside Biomedical Inc has a staff strength of 36 employees.

Stock update

Shares of Clearside Biomedical Inc opened at $0.96 at the start of the last trading session i.e. 2023-03-30.

The stocks traded within a range of $0.95 - $0.98, and closed at $0.96.

This is a -0.31% slip from the previous day's closing price.

A total volume of 87,259 shares were traded at the close of the day’s session.

In the last one week, shares of Clearside Biomedical Inc have slipped by -5.25%.

Clearside Biomedical Inc's Key Ratios

Clearside Biomedical Inc has a market cap of $58.56 million, indicating a price to book ratio of 3.927 and a price to sales ratio of 2.6392.

In the last 12-months Clearside Biomedical Inc’s revenue was $1.33 million with a gross profit of $1.12 million and an EBITDA of $-30132000. The EBITDA ratio measures Clearside Biomedical Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Clearside Biomedical Inc’s operating margin was -2281.61% while its return on assets stood at -40.17% with a return of equity of -135.64%.

In Q4, Clearside Biomedical Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 98.7%.

Clearside Biomedical Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-0.5 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Clearside Biomedical Inc’s profitability.

Clearside Biomedical Inc stock is trading at a EV to sales ratio of 0.7441 and a EV to EBITDA ratio of -4.8278. Its price to sales ratio in the trailing 12-months stood at 2.6392.

Clearside Biomedical Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$51.30 million

Total Liabilities

$5.78 million

Operating Cash Flow

$-91000.00

Capital Expenditure

$154754

Dividend Payout Ratio

0%

Clearside Biomedical Inc ended 2023 with $51.30 million in total assets and $0 in total liabilities. Its intangible assets were valued at $51.30 million while shareholder equity stood at $10.61 million.

Clearside Biomedical Inc ended 2023 with $0 in deferred long-term liabilities, $5.78 million in other current liabilities, 61000.00 in common stock, $-288438000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $48.26 million and cash and short-term investments were $48.26 million. The company’s total short-term debt was $349,000 while long-term debt stood at $0.

Clearside Biomedical Inc’s total current assets stands at $49.40 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.05 million and inventory worth $0.

In 2023, Clearside Biomedical Inc's operating cash flow was $-91000.00 while its capital expenditure stood at $154754.

Comparatively, Clearside Biomedical Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$0.96

52-Week High

$2.54

52-Week Low

$0.9

Analyst Target Price

$5.8

Clearside Biomedical Inc stock is currently trading at $0.96 per share. It touched a 52-week high of $2.54 and a 52-week low of $2.54. Analysts tracking the stock have a 12-month average target price of $5.8.

Its 50-day moving average was $1.24 and 200-day moving average was $1.33 The short ratio stood at 2.17 indicating a short percent outstanding of 0%.

Around 745.2% of the company’s stock are held by insiders while 2815.8% are held by institutions.